German biotech Disco Pharmaceuticals today announced an exclusive license agreement with US biotech major Amgen to advance ...

Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 ...

Chinese biopharma Hutchmed today announces that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib ...

Industry groups are urging changes to the US Food and Drug Administration’s User Fee Amendments programme as talks begin on ...

German contract development and manufacturing company ProBioGen has announced the signing of a master service agreement (MSA) ...

New York-based clinical-stage biotech LB Pharmaceuticals had announced the appointments of Ellen Rose as senior vice ...

US biotech BostonGene has struck a research collaboration with British pharma AstraZeneca (LSE: AZN) to explore the use of ...

US healthcare major Johnson & Johnson (NYSE: JNJ) has submitted a Type II variation to the European Medicines Agency seeking ...

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of ...

US biotech major Amgen has announced its acquisition of privately-held UK firm Dark Blue Therapeutics, a biotech advancing ...

Earendil Labs, a US AI-driven R&D next-generation biologics therapeutics start-up, has announced an expanded strategic ...

T, an in-situ platform combination immunotherapy optimized for solid tumor cancers, has announced the appointment of Stephen ...